查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1503439

到 2030 年核准藥物測試 (LDT) 市場預測：按產品、測試類型、應用、最終用戶和地區進行的全球分析

Laboratory-Developed Testing Market Forecasts to 2030 - Global Analysis By Product (Mass Spectrometry, Microarrays and Next-Generation Sequencing ), Test Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球核准藥物檢測 (LDT) 市場規模為 58.6 億美元，預計到 2030 年將達到 101.6 億美元，預測期內複合年成長率為 9.6%。

核准藥物測試 (LDT) 是在臨床或研究環境中的單一實驗室內創建、檢驗和執行的診斷測試。與商業化測試不同，LDT 通常旨在滿足特定實驗室或患者群體的特定需求。 LDT 的範圍從簡單的測定到複雜的分子測試，為疾病、遺傳傾向和治療方法提供了寶貴的見解。 LDT 在促進個人化醫療和縮小診斷能力差距方面發揮著重要作用。

根據世界衛生組織 (WHO) 的數據，癌症已成為 183 個國家中 112 個國家 70 歲以上人口的第一或第二大死因，並已成為其他 23 個國家的第三或第四大死因。

增加與遺傳健康風險相關的產品供應

隨著基因檢測變得越來越普遍，人們對全面了解健康風險的需求也越來越大。這正在推動非核准測試（LDT）市場產品陣容的擴大。公司正在擴大其產品組合，包括評估更廣泛的遺傳健康風險的測試，以滿足消費者的多樣化需求。這些產品包括各種疾病易感性、藥物基因組學、血統追蹤等測試。透過提供多樣化的產品，LDT 提供者旨在滿足醫療保健專業人員和消費者不斷變化的需求，同時滿足人們對個人化醫療和預防性醫療保健策略日益成長的興趣。

嚴格規定

嚴格的監管對 LDT 市場構成了重大限制，影響了創新和市場准入。這些法規通常由 FDA 等監管機構執行，要求對 LDT 進行嚴格的驗證和合規標準，從而增加了開發時間和成本。公司在複雜的監管途徑中面臨障礙，限制了他們快速引入新測試的能力。此外，不斷變化的法規需要不斷適應，進一步增加了合規性挑戰。

個人化醫療的持續研究

對個人化藥物的持續研究正在非核准測試（LDT）市場創造重大機會。隨著基因組學和分子生物學的進步加速，個人化治療越來越成為現實。這一趨勢推動了對準確診斷工具的需求，並促使實驗室在 LDT 方面進行創新，以實現個人化治療策略。透過持續研究，LDT 可以增強其分析基因突變和生物標記的能力，以幫助定製藥物治療方案。這一演變與精準醫療的轉變相吻合，並為 LDT 領域的成長和創新提供了一條充滿希望​​的途徑。

執行診斷測試時面臨的業務障礙

進行診斷測試時常會出現行政障礙。這些障礙包括法規遵循的複雜性、驗證和品管的資源有限以及不同實驗室標準化程序的挑戰。此外，試劑和設備的一致供應鏈管理也是一個問題。現有醫療保健系統和資料管理平台的互通性問題使營運環境更加複雜。

COVID-19 的影響：

COVID-19 的疫情對核准藥物檢測（LDT）市場產生了重大影響。隨著對準確診斷測試的迫切需求，對LDT，特別是COVID-19檢測套組的需求正在迅速增加。這種不斷成長的需求導致了對 LDT 研發的投資增加，並加強了監管監督，以確保測試的準確性和可靠性。此外，疫情也刺激了 LDT 技術的創新，促進了更快、更靈敏、更擴充性的測試解決方案的開發。然而，供應鏈中斷和監管挑戰也阻礙了市場成長。

預計在預測期內重症加護行業將是最大的

由於多種因素，核准藥物檢測 (LDT) 市場的重症加護領域正在顯著成長。醫療技術的進步推動了需求的成長，推動了更複雜的測試的開發，這些測試可以快速評估急診患者的關鍵健康指標。慢性病的增加需要對重症患者進行頻繁監測，並增加了對專門檢測的需求。此外，COVID-19 大流行凸顯了快速、準確診斷的重要性，進一步加速了 LDT 在重症加護中的採用。 LDT 提供的可自訂性和靈活性使醫療保健專業人員能夠根據特定患者的需求量身定做測試，從而增強臨床決策。

預計遺傳學在預測期內的複合年成長率最高

在核准藥物檢測（LDT）市場中，遺傳學領域正在經歷顯著的成長。基因組研究的進展揭示了有關疾病機制和個人化醫療的新知識，增加了對基因檢測的需求。此外，基因定序技術成本的下降使得醫療保健專業人員和患者更容易獲得這些測試。此外，遺傳疾病的日益普及以及人們對早期檢測和預防重要性的認知不斷增強，正在推動基因檢測服務的採用。這些測試為疾病風險評估、診斷、治療選擇和監測提供了有價值的資訊，使其對現代醫療保健至關重要。

佔比最大的地區：

最近的趨勢表明，歐洲的核准藥物檢測（LDT）市場正在經歷顯著成長。這種成長是由多種因素推動的，包括對個人化醫療和診斷的需求增加、實現更複雜測試的技術進步以及對醫療保健品質和效率的日益關注。此外，歐洲的支持性法規環境和強大的醫療保健基礎設施促進了 LDT 的創新和投資。因此，該地區檢測設施激增，為各種臨床需求提供專門的檢測服務。

複合年成長率最高的地區：

由於多種因素，北美核准藥物檢測（LDT）市場正在經歷顯著成長。對個人化醫療和精準診斷的需求不斷成長正在推動 LDT 服務的擴展。此外，次世代定序和分子診斷等技術的進步正在擴大 LDT 產品的範圍。該地區的監管靈活性也促進了創新並加速了 LDT 的採用。此外，COVID-19 的爆發凸顯了非核准檢測的重要性，進一步提振了市場。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球臨床檢測市場：按產品

  • 質譜
  • 微陣列
  • 聚合酵素鏈鎖反應(PCR)
  • 次世代定序（NGS）

第6章全球核准藥物測試（LDT）市場：依測試類型

  • 微生物
  • 免疫
  • 加護治療
  • 臨床生物化學
  • 血
    • 血球計數測試
    • 凝血和止血
    • 血紅素測試
  • 分子診斷

第7章 全球核准藥物測試（LDT）市場：依應用分類

  • 研究與發展（R&D）
  • 腫瘤學
  • 神經病學
  • 感染疾病
  • 遺傳學
  • 自體免疫疾病
  • 商業服務

第8章 全球核准藥物測試 (LDT) 市場：按最終用戶分類

  • 專業診斷中心
  • 學術機構
  • 醫院實驗室
  • 臨床研究所
  • 其他最終用戶

第9章按地區分類的全球核准藥物檢測（LDT）市場

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Epic Sciences, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • Genoptix, Inc.
  • Guardant Health
  • Illumina, Inc.
  • OPKO Health Inc.
  • Qiagen
  • Quidel Corporation
  • Rosetta Genomics Ltd.
  • Siemens Healthcare Private Limited
  • Sonic Healthcare Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: SMRC26610

According to Stratistics MRC, the Global Laboratory-Developed Testing Market is accounted for $5.86 billion in 2024 and is expected to reach $10.16 billion by 2030 growing at a CAGR of 9.6% during the forecast period. Laboratory-developed testing (LDT) refers to diagnostic tests created, validated, and performed within a single laboratory, often in clinical or research settings. Unlike commercially available tests, LDTs are typically designed to meet the specific needs of a particular laboratory or patient population. They can range from simple assays to complex molecular tests, providing valuable insights into diseases, genetic predispositions, and treatment options. LDTs play a crucial role in advancing personalized medicine and filling gaps in diagnostic capabilities.

According to the World Health Organization, cancer is the leading or second-leading cause of death for those over the age of 70 in 112 of 183 nations, and third or fourth in the other 23 countries.

Market Dynamics:

Driver:

Increasing product offerings related to genetic health risks

As genetic testing becomes more prevalent, there's a growing demand for comprehensive insights into health risks. This driver fuels the expansion of product offerings within the Laboratory-Developed Testing (LDT) market. Companies are broadening their portfolios to include tests that assess a wider range of genetic health risks, catering to diverse consumer needs. These offerings may encompass tests for predispositions to various diseases, pharmacogenomics, and ancestry tracing, among others. By diversifying their products, LDT providers aim to meet the evolving demands of healthcare professionals and consumers while also capitalizing on the increasing interest in personalized medicine and preventive healthcare strategies.

Restraint:

Stringent regulations

Stringent regulations pose significant restraints in the Laboratory Developed Testing (LDT) market, impacting innovation and market entry. These regulations, often enforced by regulatory bodies like the FDA, require rigorous validation and compliance standards for LDTs, increasing the time and cost of development. Companies face hurdles in navigating complex regulatory pathways, limiting their ability to introduce new tests swiftly. Moreover, the evolving nature of regulations necessitates continuous adaptation, further adding to compliance challenges.

Opportunity:

Continuous research on personalized medicines

Continuous research on personalized medicines presents a significant opportunity within the Laboratory Developed Testing (LDT) market. As advancements in genomics and molecular biology accelerate, tailored therapies become increasingly viable. This trend drives the demand for precise diagnostic tools, prompting laboratories to innovate LDTs for individualized treatment strategies. With ongoing research, LDTs can enhance their capabilities to analyze genetic variations and biomarkers, aiding in the customization of medication regimens. This evolution aligns with the shift towards precision medicine, offering a promising avenue for growth and innovation in the LDT sector.

Threat:

Operational barriers faced in conducting diagnostic tests

Operational barriers often arise when conducting diagnostic tests. These hurdles may include regulatory compliance complexities, limited resources for validation and quality control, and challenges in standardizing procedures across different laboratories. Additionally, ensuring consistent supply chain management for reagents and equipment can be problematic. Interoperability issues with existing healthcare systems and data management platforms further complicate the operational landscape.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the laboratory-developed testing (LDT) market. With the urgent need for accurate diagnostic testing, there has been a surge in demand for LDTs, particularly for COVID-19 testing kits. This heightened demand has led to increased investment in LDT research and development, as well as regulatory scrutiny to ensure test accuracy and reliability. Furthermore, the pandemic has spurred innovation in LDT technologies, driving the development of faster, more sensitive, and more scalable testing solutions. However, supply chain disruptions and regulatory challenges have also posed obstacles to market growth.

The critical care segment is expected to be the largest during the forecast period

The Critical Care segment within the Laboratory Developed Testing (LDT) market is experiencing notable growth due to several factors. Advancements in medical technology have enabled the development of more sophisticated tests that can rapidly assess critical health indicators in acutely ill patients, driving demand. The rising prevalence of chronic diseases necessitates frequent monitoring of patients in critical care settings, fueling the need for specialized tests. Additionally, the COVID-19 pandemic has underscored the importance of rapid and accurate diagnostics, further boosting the adoption of LDTs in critical care. The customization and flexibility offered by LDTs allow healthcare providers to tailor tests to specific patient needs, enhancing clinical decision-making.

The Genetics segment is expected to have the highest CAGR during the forecast period

In the Laboratory Developed Testing (LDT) market, the genetics segment is experiencing notable growth. Advances in genomic research have unveiled new insights into disease mechanisms and personalized medicine, driving demand for genetic testing. Moreover, the declining cost of genetic sequencing technologies has made such tests more accessible to healthcare providers and patients. Additionally, the increasing prevalence of genetic disorders and the growing awareness of the importance of early detection and prevention are fuelling the adoption of genetic testing services. These tests offer valuable information for disease risk assessment, diagnosis, treatment selection, and monitoring, making them integral to modern healthcare practices.

Region with largest share:

In recent years, Europe has experienced significant growth in the Laboratory-Developed Testing (LDT) market. This growth can be attributed to several factors, including increasing demand for personalized medicine and diagnostics, advancements in technology enabling more sophisticated testing methods, and a rising emphasis on healthcare quality and efficiency. Additionally, Europe's supportive regulatory environment and robust healthcare infrastructure have fostered innovation and investment in LDT. As a result, the region has witnessed a proliferation of laboratories offering specialized testing services, catering to diverse clinical needs.

Region with highest CAGR:

The Laboratory-Developed Testing (LDT) market in North America has witnessed substantial growth driven by several factors. Increased demand for personalized medicine and precision diagnostics has propelled the expansion of LDT services. Additionally, advancements in technology, such as next-generation sequencing and molecular diagnostics, have widened the scope of LDT offerings. Regulatory flexibility in the region has also fostered innovation and accelerated the adoption of LDTs. Moreover, the COVID-19 pandemic has highlighted the importance of diagnostic testing, further boosting the market.

Key players in the market

Some of the key players in Laboratory-Developed Testing market include Abbott Laboratories, Adaptive Biotechnologies, Bio-Rad Laboratories, Inc., Bruker Corporation, Epic Sciences, Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd, Genoptix, Inc., Guardant Health, Illumina, Inc., OPKO Health Inc., Qiagen, Quidel Corporation, Rosetta Genomics Ltd., Siemens Healthcare Private Limited, Sonic Healthcare Ltd. and Thermo Fisher Scientific Inc.

Key Developments:

In June 2024, Bruker Corporation launches the new top-of-the-line timsTOF Ultra 2 system with significantly further enhanced sensitivity for deep profiling of small cells, subcellular organelles, as well as increased sample loading flexibility. Together with new Spectronaut 19 software and the novel PreOmics ENRICHplus kit, Bruker is setting new 4D-Proteomics standards from highest sensitivity to large-scale, deep plasma proteomics.

In March 2024, Global healthcare leader Abbott has announced the launch of its innovative automation solutions, GLP systems Track, to support laboratories' high-volume needs. With this launch, Abbott aims to strike a balance between quality of care and efficient use of resources. Across different care settings, depending on laboratory size and patient pool, this automation solution can handle bulk test tubes per day.

Products Covered:

  • Mass Spectrometry
  • Microarrays
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)

Test Types Covered:

  • Microbiology
  • Immunology
  • Critical Care
  • Clinical Biochemistry
  • Haematology
  • Molecular Diagnostics

Applications Covered:

  • Research and Development (R&D)
  • Oncology
  • Neurology
  • Infectious Diseases
  • Genetics
  • Autoimmune Disorders
  • Commercial Service

End Users Covered:

  • Specialty Diagnostics Centers
  • Academic Institutes
  • Hospital Laboratories
  • Clinical Research Organizations
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Laboratory-Developed Testing Market, By Product

  • 5.1 Introduction
  • 5.2 Mass Spectrometry
  • 5.3 Microarrays
  • 5.4 Polymerase Chain Reaction (PCR)
  • 5.5 Next-Generation Sequencing (NGS)

6 Global Laboratory-Developed Testing Market, By Test Type

  • 6.1 Introduction
  • 6.2 Microbiology
  • 6.3 Immunology
  • 6.4 Critical Care
  • 6.5 Clinical Biochemistry
  • 6.6 Haematology
    • 6.6.1 Blood Count Testing
    • 6.6.2 Coagulation and Hemostasis
    • 6.6.3 Hemoglobin Testing
  • 6.7 Molecular Diagnostics

7 Global Laboratory-Developed Testing Market, By Application

  • 7.1 Introduction
  • 7.2 Research and Development (R&D)
  • 7.3 Oncology
  • 7.4 Neurology
  • 7.5 Infectious Diseases
  • 7.6 Genetics
  • 7.7 Autoimmune Disorders
  • 7.8 Commercial Service

8 Global Laboratory-Developed Testing Market, By End User

  • 8.1 Introduction
  • 8.2 Specialty Diagnostics Centers
  • 8.3 Academic Institutes
  • 8.4 Hospital Laboratories
  • 8.5 Clinical Research Organizations
  • 8.6 Other End Users

9 Global Laboratory-Developed Testing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Laboratories
  • 11.2 Adaptive Biotechnologies
  • 11.3 Bio-Rad Laboratories, Inc.
  • 11.4 Bruker Corporation
  • 11.5 Epic Sciences, Inc.
  • 11.6 Eurofins Scientific
  • 11.7 F. Hoffmann-La Roche Ltd
  • 11.8 Genoptix, Inc.
  • 11.9 Guardant Health
  • 11.10 Illumina, Inc.
  • 11.11 OPKO Health Inc.
  • 11.12 Qiagen
  • 11.13 Quidel Corporation
  • 11.14 Rosetta Genomics Ltd.
  • 11.15 Siemens Healthcare Private Limited
  • 11.16 Sonic Healthcare Ltd.
  • 11.17 Thermo Fisher Scientific Inc.

List of Tables

  • Table 1 Global Laboratory-Developed Testing Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Laboratory-Developed Testing Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Laboratory-Developed Testing Market Outlook, By Mass Spectrometry (2022-2030) ($MN)
  • Table 4 Global Laboratory-Developed Testing Market Outlook, By Microarrays (2022-2030) ($MN)
  • Table 5 Global Laboratory-Developed Testing Market Outlook, By Polymerase Chain Reaction (PCR) (2022-2030) ($MN)
  • Table 6 Global Laboratory-Developed Testing Market Outlook, By Next-Generation Sequencing (NGS) (2022-2030) ($MN)
  • Table 7 Global Laboratory-Developed Testing Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 8 Global Laboratory-Developed Testing Market Outlook, By Microbiology (2022-2030) ($MN)
  • Table 9 Global Laboratory-Developed Testing Market Outlook, By Immunology (2022-2030) ($MN)
  • Table 10 Global Laboratory-Developed Testing Market Outlook, By Critical Care (2022-2030) ($MN)
  • Table 11 Global Laboratory-Developed Testing Market Outlook, By Clinical Biochemistry (2022-2030) ($MN)
  • Table 12 Global Laboratory-Developed Testing Market Outlook, By Haematology (2022-2030) ($MN)
  • Table 13 Global Laboratory-Developed Testing Market Outlook, By Blood Count Testing (2022-2030) ($MN)
  • Table 14 Global Laboratory-Developed Testing Market Outlook, By Coagulation and Hemostasis (2022-2030) ($MN)
  • Table 15 Global Laboratory-Developed Testing Market Outlook, By Hemoglobin Testing (2022-2030) ($MN)
  • Table 16 Global Laboratory-Developed Testing Market Outlook, By Molecular Diagnostics (2022-2030) ($MN)
  • Table 17 Global Laboratory-Developed Testing Market Outlook, By Application (2022-2030) ($MN)
  • Table 18 Global Laboratory-Developed Testing Market Outlook, By Research and Development (R&D) (2022-2030) ($MN)
  • Table 19 Global Laboratory-Developed Testing Market Outlook, By Oncology (2022-2030) ($MN)
  • Table 20 Global Laboratory-Developed Testing Market Outlook, By Neurology (2022-2030) ($MN)
  • Table 21 Global Laboratory-Developed Testing Market Outlook, By Infectious Diseases (2022-2030) ($MN)
  • Table 22 Global Laboratory-Developed Testing Market Outlook, By Genetics (2022-2030) ($MN)
  • Table 23 Global Laboratory-Developed Testing Market Outlook, By Autoimmune Disorders (2022-2030) ($MN)
  • Table 24 Global Laboratory-Developed Testing Market Outlook, By Commercial Service (2022-2030) ($MN)
  • Table 25 Global Laboratory-Developed Testing Market Outlook, By End User (2022-2030) ($MN)
  • Table 26 Global Laboratory-Developed Testing Market Outlook, By Specialty Diagnostics Centers (2022-2030) ($MN)
  • Table 27 Global Laboratory-Developed Testing Market Outlook, By Academic Institutes (2022-2030) ($MN)
  • Table 28 Global Laboratory-Developed Testing Market Outlook, By Hospital Laboratories (2022-2030) ($MN)
  • Table 29 Global Laboratory-Developed Testing Market Outlook, By Clinical Research Organizations (2022-2030) ($MN)
  • Table 30 Global Laboratory-Developed Testing Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.